Top in hem/onc: Multiple myeloma salvage therapy; revaccination guidance after cell therapy
Click Here to Manage Email Alerts
Patients with multiple myeloma who relapse after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy may benefit from “subsequent T-cell redirection,” according to researchers.
The findings support clinical trials investigating the sequence of T-cell-engaging therapies to optimize outcomes for patients with multiple myeloma, Samir Parekh, MD, director of translational research in multiple myeloma and co-leader of the Cancer Clinical Investigation program at The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, told Healio. It was the top story in hematology/oncology last week.
Another top story was about recommendations on revaccination for vaccine-preventable diseases, including COVID-19 and seasonal influenza, after cell therapy.
Read these and more top stories in hematology/oncology below:
Salvage therapies may benefit patients with multiple myeloma who relapse after CAR-T
Salvage therapies appeared to maintain clinical activity among patients with relapsed/refractory multiple myeloma who relapsed after B-cell maturation antigen-directed CAR T-cell therapy, according to study results. Read more.
Revaccination guidance after cell therapy established for some, ‘evolving’ for others
Guidelines on revaccination after cell therapy are clear for some patients but lack evidence-based consensus for others, according to an expert in infectious disease who spoke at NCCN 2022 Annual Congress: Hematologic Malignancies. Read more.
Cancer cell therapy for melanoma has potential to save ‘thousands’ of lives each year
A single dose of lifileucel conferred an objective response in nearly one-third of patients with advanced unresectable or metastatic melanoma, results from the phase 2 C-144-01 trial showed. Read more.
Experimental breast cancer vaccine generates immune response to key tumor protein
An experimental plasmid DNA vaccine produced a strong immune response to the HER2 protein among women with advanced HER2-positive breast cancer, according to results of a single-arm, phase 1 study published in JAMA Oncology. Read more.
Women oncologists face difficult career choices, biased practices when planning a family
Women oncologists reported encountering difficult career choices and discriminatory practices when planning for a family, according to survey results published in JAMA Network Open. Read more.